Apafant
Alternative Names: DE 081; WEB 2086; WEB 2086BSLatest Information Update: 18 May 2004
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antiarrhythmics; Antiasthmatics; Antiplatelets; Morpholines
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma; Thrombosis
- Discontinued Allergic conjunctivitis; Arrhythmias; Peptic ulcer; Transplant rejection
Most Recent Events
- 31 Dec 2003 Discontinued - Phase-II for Allergic conjunctivitis in Japan (unspecified route)
- 10 Oct 2003 This compound is still in active development
- 31 Mar 2001 Phase-II clinical trials for Allergic conjunctivitis in Japan (Unknown route)